The global antibiotics active pharmaceutical ingredient (API) market is projected to achieve a valuation of USD 8,653.0 million in 2023 and is expected to grow to USD 12,002.3 million by 2033, registering a CAGR of 3.3% over the forecast period. The increasing incidence of bacterial infections, along with the rising demand for antibiotics, is expected to be a significant driver for market growth.
As the global healthcare landscape evolves, the demand for effective antibiotics continues to rise, particularly with the increasing prevalence of infectious diseases and antibiotic-resistant bacteria. The need for antibiotics to treat conditions like pneumonia, tuberculosis, urinary tract infections, and sepsis, among others, continues to drive the market forward. Additionally, the expanding healthcare expenditures and increasing investments in biopharmaceuticals and generic medicines are further propelling market growth.
The market is also benefiting from the ongoing development of new-generation antibiotics and antibiotic combinations, aimed at addressing the growing challenges posed by drug-resistant pathogens. Governments and healthcare organizations across the globe are prioritizing the fight against antimicrobial resistance (AMR), which is expected to bolster the demand for advanced antibiotic formulations.
Key Takeaways:
- The antibiotics API market is expected to grow from USD 8,653.0 million in 2023 to USD 12,002.3 million by 2033, at a CAGR of 3.3%.
- Rising rates of bacterial infections and antibiotic resistance are major factors driving the demand for antibiotics.
- Increased healthcare spending and government support for antimicrobial research are fueling market growth.
- The market is witnessing the introduction of new antibiotics and combination therapies to address resistant strains of bacteria.
Key Growth Drivers
- Increasing Prevalence of Bacterial Infections: The rising incidence of bacterial infections and other infectious diseases is a significant driver for market growth, as more patients require antibiotic treatments.
- Rising Healthcare Expenditure: Increased investments in healthcare are facilitating the development and availability of antibiotic drugs, supporting market expansion.
- Growing Approvals for Generic Drugs: The rise in approvals for generic antibiotic drugs is making treatments more accessible and affordable, further boosting demand.
Market Dynamics
- The market is characterized by a robust demand for various antibiotic APIs, driven by the need for effective treatment options in response to growing health challenges.
- Research and development activities aimed at discovering new antibiotic molecules are expected to enhance market revenue and provide opportunities for manufacturers.
Market Competition
The antibiotics active pharmaceutical ingredient (API) market is extremely competitive and consists of various key industry players. These players are heavily investing in manufacturing antibiotics active pharmaceutical ingredients (API).
The key industry players are Centrient Pharmaceuticals, ACS DOBFAR SPA, Nanjing Dorra Pharmaceutical Technology Co. Ltd., Parabolic Drugs Ltd., Sandoz International GmbH, DAEWOONG PHARMACEUTICAL CO. LTD., Penam Laboratories Ltd., ASIATIC DRUGS & PHARMACEUTICALS PVT. LTD., Fresenius Kabi, The United Laboratories International Holdings Limited, CordenPharma International, Aurobindo Pharma Limited, Unimark Remedies Ltd., Savior Lifetec, Shenzhen Haibin Pharmaceutical Co., Ltd., Sterile India Pvt. Ltd., Zhejiang Jiuzhou Pharmaceutical Co. Ltd., Kyongbo Pharm.
Some recent developments in the market are:
Key industry players leverage organic growth strategies like acquisition, mergers, partnerships, and collaboration to enhance their product portfolio. This is expected to fuel the global antibiotics active pharmaceutical ingredient (API) market.
- On May 9, 2023, Sandoz International GmbH, a global leader in off-patent medicines, announced a multi-year partnership with Just – Evotec Biologics, a subsidiary of Evotec SE.
- Sandoz International GmbH recently revealed a distribution and collaboration agreement with Adalvo, granting exclusive commercialization rights for six products in the United States. These products span important therapeutic areas such as antifungal/antibiotic, oncology, and pulmonary. The agreement, announced on May 4, 2023, strengthens Sandoz’s presence in these key therapeutic domains.
- Glenmark Pharmaceuticals Limited introduced the SUTIB oral capsule in three different doses: 12.5 mg, 25 mg, and 50 mg. This oral multi-kinase inhibitor specifically targets kidney cancer. The launch of SUTIB was announced in February 2021.
Key Companies Profiled
Sandoz International GmbH; Centrient Pharmaceuticals; CordenPharma International; ACS DOBFAR SPA; Nanjing Dorra Pharmaceutical Technology Co. Ltd.; DAEWOONG PHARMACEUTICAL CO. LTD.; Parabolic Drugs Ltd.; Penam Laboratories Ltd.; ASIATIC DRUGS & PHARMACEUTICALS PVT. LTD.; Fresenius Kabi; The United Laboratories International Holdings Limited; Aurobindo Pharma Limited; Unimark Remedies Ltd.; Savior Lifetec; Shenzhen Haibin Pharmaceutical Co., Ltd.; Sterile India Pvt. Ltd.; Zhejiang Jiuzhou Pharmaceutical Co. Ltd.; Kyongbo Pharm
Full Report Revealed
Key segments profiled in the antibiotics active pharmaceutical ingredient (API) market Industry survey
By API Type:
- Penicillin Antibiotics
- Ampicillin
- Amoxicillin
- Dicloxacillin
- Penicillin G Sodium
- Benzathine
- Procaine
- Cephalosporins
- Cefotaxime
- Ceftriaxone
- Cefuroxime
- Cefalotin
- Carbapenem Antibiotics
- Meropenem
- Imipenem
- Ertapenem
By End User:
- Pharmaceutical Companies
- Contract Manufacturing Organizations (CMOs)
- Contract Development & Manufacturing Organizations (CDMOs)
By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
